Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Stock Short Interest Report for September

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 89,454 shares, a decrease of 40.3% from the September 15th total of 149,890 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 114,595 shares, the short-interest ratio is currently 0.8 days.

Phio Pharmaceuticals Stock Performance

NASDAQ:PHIO traded down $0.05 during trading hours on Friday, hitting $0.87. The company’s stock had a trading volume of 91,131 shares, compared to its average volume of 107,480. Phio Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $4.19. The business’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.09. The company has a market capitalization of $10.12 million, a PE ratio of -0.68 and a beta of 0.84.

Phio Pharmaceuticals (NASDAQ:PHIO) last issued its earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, hitting the consensus estimate of ($0.36). As a group, analysts predict that Phio Pharmaceuticals will post -1.45 EPS for the current fiscal year.

Analyst Ratings Changes

PHIO has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Phio Pharmaceuticals in a report on Wednesday, August 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Thursday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Phio Pharmaceuticals presently has an average rating of “Hold” and an average target price of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing immuno-oncology treatments based on its INTASYL self-delivering RNAi technology. The platform is designed to enable small interfering RNA (siRNA) molecules to enter cells without the use of conventional delivery vehicles and to reduce the expression of selected genes involved in cancer biology and immune-system activity.

The company’s pipeline has included product candidates intended to improve the ability of immune cells to recognize and destroy tumors.